insulin glargine news

All news on insulin glargine (also known as Lantus, Basaglar, Toujeo, and (GlyA21,ArgB31,ArgB32)human insulin): plants, production capacities, investments and involved companies.

8 June 2026

Lilly's Foundayo (orforglipron) outperforms oral semaglutide, dapagliflozin and placebo in ACHIEVE trials

Oral GLP‑1 orforglipron reduced A1C and body weight more than oral semaglutide, dapagliflozin or placebo across three Phase‑3 trials; FDA filing planned by end of Q2 2026.
16 April 2026

Lilly ACHIEVE‑4 confirms Foundayo cardiovascular safety and cardiometabolic benefits

ACHIEVE-4: Foundayo non-inferior vs insulin glargine for MACE-4 (HR 0.84); improved A1C (-1.6 vs -1.0) and weight (-8.8% vs +1.7%) at 52 wks; 57% lower all-cause death; GI AEs; FDA filing planned.

Who will be producing insulin glargine in the future?

Find out with chemXplore Alpha

Learn more